March, 2025
March 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
24252627282930
31  
Rasha Aboelhassan: Impressed by the results of the investigator-initiated TalaCom study
Mar 9, 2025, 05:14

Rasha Aboelhassan: Impressed by the results of the investigator-initiated TalaCom study

Rasha Aboelhassan, Senior Oncology Consultant at Nasser Institute Hospital, shared a post on LinkedIn:

“Cancer fighting is not only about treating patients.

It’s about finding new lines of treatment that can overcome resistance clones that grow every day.

I was impressed by reading the results of the investigator-initiated TalaCom study provide early evidence in favour of combining the PARP1/2 inhibitor talazoparib with the VEGFR inhibitor axitinib in patients with BRCA1/2 wildtype high-grade serous ovarian oe molecularly unselected metastatic castration-resistant prostate cancer.

This results will give chance for survival as well as Quality of life for patients in late stages of cancer. Thanks for all investigators.”

More posts featuring Rasha Aboelhassan.